These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7831443)

  • 21. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
    Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
    Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of 5-HT2A receptors in antipsychotic activity.
    Schmidt CJ; Sorensen SM; Kehne JH; Carr AA; Palfreyman MG
    Life Sci; 1995; 56(25):2209-22. PubMed ID: 7791509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of serotonin(2C) receptors in the control of brain dopaminergic function.
    Di Matteo V; Cacchio M; Di Giulio C; Esposito E
    Pharmacol Biochem Behav; 2002 Apr; 71(4):727-34. PubMed ID: 11888564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
    Alex KD; Pehek EA
    Pharmacol Ther; 2007 Feb; 113(2):296-320. PubMed ID: 17049611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor.
    Cheetham SC; Heal DJ
    Br J Pharmacol; 1993 Dec; 110(4):1621-9. PubMed ID: 8306109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 28. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.
    Akunne HC; Zoski KT; Davis MD; Cooke LW; Meltzer LT; Whetzel SZ; Shih YH; Wustrow DJ; Wise LD; MacKenzie RG; Georgic LM; Heffner TG; Pugsley TA
    Neuropharmacology; 2000 Apr; 39(7):1197-210. PubMed ID: 10760362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroleptics and serotonin].
    Hery F; Hamon M
    Encephale; 1993; 19(5):525-32. PubMed ID: 7905821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the potent 5-HT1A receptor agonist, alnespirone (S-20499), affecting dopaminergic systems in the rat brain?
    Dugast C; Soulière F; Schmitt P; Casanovas JM; Fattaccini CM; Mocaër E; Lesourd M; Renaud B; Artigas F; Hamon M; Chouvet G
    Eur J Pharmacol; 1998 Jun; 350(2-3):171-80. PubMed ID: 9696405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opportunities for treatment of psychoactive substance use disorders with serotonergic medications.
    Sellers EM; Higgins GA; Tomkins DM; Romach MK; Toneatto T
    J Clin Psychiatry; 1991 Dec; 52 Suppl():49-54. PubMed ID: 1752860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The breadth of action of the 5-HT3 receptor antagonists.
    Costall B
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():3-9. PubMed ID: 8201244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study.
    Gurevich EV; Joyce JN
    Biol Psychiatry; 1997 Oct; 42(7):529-45. PubMed ID: 9376449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.